Kornimate/medical-research-clean huggingface dataset:
efficacy park study assessing rhinix™ nasal filters for hay fever

Conditions: Seasonal Allergic Rhinitis

Summary: this study will evaluate the effects of rhinix™ nasal filters on seasonal allergic rhinitis (hay fever) in a park setting.

the study will include 100 participants with grass allergy and will look at the efficacy and usability of rhinix™ nasal filters on hay fever in a randomized, double-blind, placebo-controlled, crossover design.

Eligibility criteria:
inclusion criteria: * history of seasonal allergic rhinitis (sar) for a minimum of 2 years before study entry. documented by a positive skin test (wheal \> 3mm) within 12 months of study enrolment. * written informed consent * must be able to complete the study * reliable anticonception for fertile women * fev1 higher than 70 % of predicted value * positive grass ige blood sample higher or equal to 0,7 ku/l exclusion criteria: * improper fit of the rhinix™ device * nasal septal deviation * retrospective tnss for last summer \< 3 * positive pregnancy test for fertile women * inadequate washout periods in regards to park study appointments (intranasal or systemic corticosteroids (1month), intranasal cromolyn (2 weeks), intranasal or systemic decongestants (3 days), intranasal or systemic antihistamines (3 days), loratadine (10 days)). * rhinitis medicamentosa * use of long acting anti-histamines. * documented evidence of acute or cronic sinusitis, as determined by the individual investigator. * fev1 lower than 70 % of predicted value * subjects with nasal conditions likely to affect the outcome of the study in the opinion of the investigator, i.e. anterior nasal septum deviation, nasal septal perforations, nasal polyps, chronic nasal obstruction or other nasal diseases. * receipt of immunotherapy with grass pollen within the previous 10 years (at least two rounds of treatment). * women who are breastfeeding
bpmedmanage: digital technology to support adherence to hypertension medications

Conditions: Aging; Mild Cognitive Impairment; Hypertension

Summary: the purpose of the bpmedmanage study is to rigorously test the efficacy of a smartphone technology to help improve high blood pressure medication adherence among older adults with mild cognitive impairment (mci) in a 16-week randomized controlled trial. a total of 100 older adults will be recruited. there will be two treatment arms, bpmedmanage-s and bpmedmanage-p with 50 participants in each arm. participants randomized into the bpmedmanage-s intervention arm will use a smartphone application with medication reminders plus receive education with standardized information on hypertension and antihypertensive medications on the education portal. participants in the bpmedmanage-p group will use a smartphone to receive education with standardized information on hypertension and antihypertensive medications on an education portal. both groups will complete baseline assessments followed by 4 weeks of medication adherence monitoring. at the end of the adherence monitoring period, participants will be randomized into one of the two treatment arms. immediate outcomes on primary and secondary measures will be assessed 4 weeks after beginning of the intervention. follow-up outcomes will be assessed 12 weeks after the beginning of the intervention.


Eligibility criteria:
inclusion criteria: 1. age 60+ 2. community-dwelling older adults 3. self-reported fluent in english 4. adequate self-reported visual and hearing ability 5. self-reported memory, thinking, or concentration challenges 6. self-manage at least one prescribed antihypertensive medication 7. have and use a smartphone 8. no self-reported history of major depression or other mental health diagnoses 9. no self-reported diagnosis of dementia or other neurological disorder such as stroke, tbi, and parkinson's disease 10. tics-m score between 27-37 and montreal cognitive assessment (moca) score between 20-26 11. willing to participate in the study for at least 4 months exclusion criteria: 1. diagnosis of dementia 2. lives in assisted living facility or skilled nursing facility

Keywords: digital health intervention medication adherence mobile application mild cognitive impairment aging hypertension
combination chemotherapy followed by peripheral stem cell transplantation in treating patients with chronic myelogenous leukemia

Conditions: Leukemia

Summary: rationale: drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. purpose: phase ii trial to study the effectiveness of combination chemotherapy followed by g-csf and peripheral stem cell transplantation in treating patients with chronic myelogenous leukemia.

objectives: i. evaluate the efficacy of mce (mitoxantrone/cytarabine/etoposide) followed by granulocyte colony-stimulating factor to mobilize peripheral blood stem cells (pbsc) in patients with chronic myeloid leukemia (cml). ii. evaluate the toxicity of this regimen. iii. evaluate the cytoreductive effects of this regimen in cml as determined by the ability to mobilize philadelphia chromosome-negative pbsc. iv. assess the time of peak cd34+ and cd34+/cd38- cell concentrations in the peripheral blood of patients treated with this regimen. outline: the following acronyms are used: ara-c cytarabine, nsc-63878 dhad mitoxantrone, nsc-301739 g-csf granulocyte colony-stimulating factor (source not specified) hu hydroxyurea, nsc-32065 mce dhad/ara-c/vp-16 vp-16 etoposide, nsc-141540 single-agent cytoreduction followed by 3-drug combination chemotherapy/stem cell mobilization. hu; followed by mce; g-csf. projected accrual: 30 patients will be entered over 3 years.

Eligibility criteria:
disease characteristics: philadelphia chromosome-positive chronic myeloid leukemia (cml) in chronic or accelerated phase ineligible for allograft protocols or no available hla-matched sibling marrow donor no patients under age 55 who have consented to unrelated donor search unless: search unsuccessful for 6 months and unlikely a donor will be found transplant from an unrelated donor declined no history of cml blast crisis no grade iii/iv myelofibrosis patient characteristics: age: over 17 to under 66 performance status: not specified life expectancy: no limitations from disease other than leukemia other: no hepatic, renal, pulmonary, or cardiac dysfunction that would preclude transplant preparative regimen no hiv antibody no active infection prior concurrent therapy: at least 1 month since interferon

Keywords: relapsing chronic myelogenous leukemia chronic phase chronic myelogenous leukemia accelerated phase chronic myelogenous leukemia philadelphia chromosome positive chronic myelogenous leukemia
stops trial: total vs subtotal colectomy for slow transit constipation

Conditions: Slow Transit Constipation; Surgery

Summary: total colectomy with ileorectal anastomosis is a traditional surgical option for slow transit constipation (stc). subtotal colectomy with caecorectal anastomosis have been reported to be a potential alternative approach. thus, the optimal surgical option for stc is controversial.

constipation, a prevalent gastrointestinal disorder, affects 10%-15% of adults in the united states and approximately 8.2% of china's general population. slow transit constipation (stc), accounting for 15%-42% of constipation cases, is characterized by impaired colonic motility. for patients refractory to conservative therapies who experience chronic, intractable symptoms and diminished quality of life (qol), surgical intervention becomes the last-resort treatment. the primary surgical approach for stc has historically been total colectomy with ileorectal anastomosis (tc-ira). over the past two decades, however, subtotal colectomy with cecorectal anastomosis (sc-cra) has garnered growing interest within the surgical community due to its potential to mitigate postoperative diarrhea. despite this benefit, sc-cra raises concerns about an elevated risk of recurrent constipation. the debate regarding the superiority of these approaches remains unresolved. this study aims to address this controversy through a comparative analysis of tc-ira and sc-cra, evaluating their therapeutic efficacy and safety profiles in refractory stc.

Eligibility criteria:
inclusion criteria 1. patients (≥18 years of age) of either sex 2. patients with conditions in agreement with the roman iv criteria of functional constipation 3. patients have less than one complete spontaneous bowel movement per week 4. patients rely on laxatives to assist defecation for a long time 5. more than 20% the radio-paque markers localized in the colon after 72 hours based on colonic transit studies 6. patients were refractory to conservative treatment for more than 1 year 7. patients with a strong desire for surgery exclusion criteria 1. pregnant or breast-feeding women 2. patients with megacolon, megarectum,severe spastic constipation, severe rectocele, rectal prolapse (oxford grade iv or above) 3. patients with colorectal neoplasms 4. patients with small intestinal slow transit 5. patients with constipation-predominant irritable bowel syndrome 6. patients with inflammatory bowel disease 7. patients with ileostomy 8. patients with severe psychiatric disease

Keywords: slow transit constipation total colectomy with ileorectal anastomosis subtotal colectomy with caecorectal anastomosis defecation function quality of life randomized controlled trial
acceptance-based healthy lifestyles program for patients with pneumoconiosis

Conditions: Pneumoconiosis; Healthy Lifestyle

Summary: symptoms, such as cough and shortness of breath, are common among patients with pneumoconiosis. depression and anxiety can be elicited by the symptoms, while avoidance of daily activities is believed to reduce trigger of symptoms. the lung function is then declined and the risk of having stroke and heart failure is increased. the objectives of this 2-arm waitlist pilot randomized controlled trial are to test the effects and feasibility of an acceptance-based educational program among patients with pneumoconiosis. 80 participants will be recruited from community centers and randomly assigned to intervention group or waitlist-control group in a ratio of 1:1. the 6-week group-based educational program will be provided to the intervention group first, then the waitlist-control group. the program consists of 4 sessions integrated with acceptance components and care of pneumoconiosis. their psychological health, healthy lifestyles, and cardiometabolic profiles will be assessed at baseline, week 6, and week 14. data will be analyzed using a statistical package. the feasibility of the program will be evaluated by interview. the findings of this study can inform the integration of acceptance-based intervention into pneumoconiosis management in hong kong, and future study on chronic progressive lung diseases.


Eligibility criteria:
inclusion criteria: 1. ethnic chinese who is able read and speak chinese. 2. adults aged 18 or over. 3. taking compensation for pneumoconiosis. exclusion criteria: 1. those who have mental, visual, hearing, or cognitive impairments with regular medical follow-ups and treatment. 2. those who are unable to give written consent.

Keywords: pneumoconiosis healthy lifestyle acceptance-based
implementation of an epidemiological and clinical registry of emergency surgery patients in a costa rican hospital

Conditions: Surgical Complication; Emergencies

Summary: a retrospective cross-sectional study was conducted in a quaternary level university hospital of the costa rican public health system. the study included all patients aged 12 years and older who required emergency surgery by the hospital's emergency surgery and trauma service, admitted through the hospital's emergency service.

this research consists in a retrospective cross-sectional study carried out in a quarterly level university hospital of care of the costa rican public health system (high complexity). the study included all patients aged 12 years or older who required emergency surgery for the hospital's emergency surgery and trauma service, admitted to this center between 2020 and 2022. only those patients who required emergency surgery by another surgical specialty during this period were excluded from the register. a non-probabilistic convenience sampling was performed, based on the pre-established selection criteria and determined by the number of patients treated in the shock room of the hospital, that subsequently received general emergency or trauma surgery in the period under study. sociodemographic variables, hemodynamic status, period of hospitalization, related to the procedure performed and the underlying comorbidities, as well as the clinical outcome, were included in the study database.

Eligibility criteria:
inclusion criteria: * the study included all patients aged 12 years and older who required emergency surgery by the hospital's emergency surgery and trauma service, admitted through the hospital's emergency service. exclusion criteria: * . only those patients who required emergency surgery by another surgical specialty during this period were excluded from the register.

Keywords: registry trauma general surgery emergency
changes in endothelial function and biomarkers in african americans (aa) with metabolic syndrome

Conditions: Hypertension

Summary: the purpose of the study is to compare the effects of azor (a combination of amlodipine and olmesartan) with hyzaar ( a combination of losartan and hydrochlorothiazide) on the thin lining on the inside of blood vessels. these cells help keep blood vessels healthy and blood pressure normal.

participants must be 18-75 years of age, african american, and have a combination of high blood pressure, insulin resistance (type 2 diabetes), low hdl cholesterol levels or obesity.

Eligibility criteria:
inclusion criteria: * african american * hypertension and one of the following: * fasting glucose \> 100 mg/dl * hga1c\> 6.0 % * plasma triglycerides \>150 * hdl cholesterol \< 40 mg/dl in men or \< 50 mg/dl in women exclusion criteria: * history of heart failure * use of insulin * non-dominant arm circ \> 50 cm.

Keywords: african american hypertension cardiometabolic syndrome
special drug use investigation for paxil tablet (investigation in case of administered from 20mg/day)

Conditions: Panic Disorder

Summary: the objective of this survey was to understand the safety and efficacy of paxil tablets ("paxil", hereinafter) when it was started at 20 mg/day in subjects with depression or in a depressed state.


Eligibility criteria:
inclusion criteria: * patients with depression or in a depressed state * patients who start taking paroxetine at 20mg a day exclusion criteria: * patients who have been treated with paroxetine prior to this investigation * patients with hypersensitivity to paroxetine * patients taking monoamine oxidase inhibitors (maois) or within 2 weeks of stopping treatment with maois * concomitant use in patients taking pimozide
remediation of emotional deficits in multiple sclerosis and traumatic brain injury

Conditions: Multiple Sclerosis; Traumatic Brain Injury

Summary: this study will examine the efficacy of a clinical intervention for improving emotional processing in individuals with ms and tbi.(1)the main outcome measure will be changes in emotional processing measures from pre to post treatment. (2)this study will also assess the impact of the emotional processing intervention on changes in pre and post treatment depression and anxiety, as well as fatigue.(3) this study will additionally measure the impact of the emotional processing intervention on cognitive functioning, specifically processing speed, attention and executive abilities. this will be accomplished through the completion of a neuropsychological battery prior to and following the completion of treatment.(4)finally, the investigators will measure the impact of the intervention on quality of life and social functioning, utilizing a pre and post treatment assessment consisting of measures of self-efficacy, quality of life, functional abilities, and awareness.


Eligibility criteria:
inclusion criteria: * diagnosis of multiple sclerosis or traumatic brain injury * fluent in english * processing speed impairment (based on evaluation) exclusion criteria: * currently taking steroids and/or benzodiazepines * prior stroke or neurological diease * history of significant pyschiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) or a current diagnosis of major depressive disorder, schizophrenia, epilepsy, bipolar disorder * significant alcohol or drug abuse history

Keywords: processing speed intervention multiple sclerosis traumatic brain injury cognition
a prospective phase ii study for adjuvant hypofractionated intensity-modulated proton radiotherapy for post operative breast cancer with implantation reconstruction

Conditions: Breast Cancer

Summary: the incidence of breast reconstruction failure after conventional photon radiotherapy for breast cancer is about 18.7%. at present, there is limited data on proton radiotherapy for post operative breast cancer with implantation reconstruction. proton radiotherapy for breast cancer can significantly reduce the radiation dose of the ipsilateral heart and lung, thereby reducing the incidence of cardiac events and radiation pneumonia. this study is aimed at the study of adjuvant hypofractionated intensity-modulated proton radiotherapy for post operative breast cancer with implantation reconstruction. it can provide an ideal treatment option for such patients to effectively protect the heart and lungs without increasing the failure rate of breast reconstruction after adjuvant radiotherapy.


Eligibility criteria:
inclusion criteria: * 1: patients with pathologically confirmed breast cancer 2: indications: patients who need adjuvant radiotherapy after mastectomy and implant reconstruction 3: no distant metastasis 4: had no chest and breast radiotherapy history 5: between the ages of 18 and 80 6: ecog general status score is 0-2,there are no serious pulmonary hypertension, cardiovascular disease, peripheral vascular disease, serious chronic heart disease and other complications that may affect the radiotherapy 7: non pregnancy (confirmed by serum or urine β- hcg test) or lactating women 8: the patient must sign the informed consent form for receiving radiotherapy. exclusion criteria: * 1: no pathological confirmation； 2: distant metastasis； 3: had chest and breast radiotherapy history 4: organs at risk could not achieve safe dose 5: pregnancy (confirmed by serum or urine β- hcg test) or lactating women 6: poor general health status, i.e. kps\ 2 7: there are serious complications that may affect the radiotherapy, including: a) unstable angina, congestive heart failure and myocardial infarction requiring hospitalization in the past 6 months； b) acute bacterial or systemic fungal infection；c) chronic obstructive pulmonary disease exacerbation or other respiratory diseases need hospitalization； d) patients with immunosuppression；e) with connective tissue disease, such as active scleroderma or lupus and other contraindications to radiotherapy； 8: unable to understand the purpose of treatment or unwilling/unable to sign informed consent.

Keywords: breast cancer hypofractionated proton radiotherapy implantation reconstruction postoperative adjuvant radiotherapy
a study of dpc 817 in hiv-infected males

Conditions: HIV Infections

Summary: the purpose of this study is to evaluate dpc 817. the safety, dosages, and how the body responds to the drug will be studied.

the study will consist of two parts. patients in part a will receive a single dose of dpc 817 on two separate occasions and a placebo (a solution or tablet without the drug) on one occasion. patients in part b will receive two separate doses of dpc 817. patients will be admitted to the clinical study unit the day before dosing (day -1) and remain there for at least 48 hours after taking the study drug. patients will return to the clinical study unit on day 8 and day 28 following the dose in the last treatment period. during the study there will be medical and medication histories taken, physical examinations, vital sign measurements, and routine clinical laboratory tests.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * are hiv positive * are male and are between 18 years of age (or the legal age of consent, whichever is older) and 55 years of age * are female and are between 18 years of age (or the legal age of consent, whichever is older) and 55 years of age and are not able to have children (females may participate in part b only) * have no clinically significant findings on physical examination or clinical laboratory evaluations * have a cd4-lymphocyte count of 50 or more cells/mm3 * are able and willing to comply with the requirements of this study exclusion criteria patients will not be eligible for this study if they: * have an opportunistic infection characteristic of aids * are receiving any approved or experimental hiv drugs. any previous anti-hiv treatment must be stopped at least 4 weeks before the first dose of study medication * are pregnant or breast-feeding * are enrolled in other experimental drug studies or have recieved other experimental drugs within 30 days before the first dose of study drug * have any disease that causes a problem with absorption of drugs * have active hepatitis * have a history of pancreatitis or peripheral neuropathy * have received radiation therapy or chemotherapy within 30 days before the first dose of study drug * have received treatment with drugs that affect the immune system within 30 days before the first dose of study drug or have received an hiv immunotherapeutic vaccine * have taken prescription or over-the-counter products within 14 days of the first dose of study drug unless approved by the doctor * are unable to comply with the dosing schedule and study procedures

Keywords: hiv phase i
digital holographic microscopy: evaluation of histological disease activity in patients with ulcerative colitis

Conditions: Colitis, Ulcerative; Inflammatory Bowel Diseases

Summary: ulcerative colitis (uc) belongs to the group of inflammatory bowel disease (ibd) and is characterized by a chronic relapsing disease course. as uncontrolled intestinal inflammation can lead to severe disease complications, treatment of uc has evolved from sole treatment of symptoms up to histological remission which is marked by the absence of histological inflammation. to correctly assess and quantify the degree of histological inflammation in ibd patients remains difficult. digital holographic microscopy (dhm) is a new imaging technique belonging to quantitative phase contrast imaging. it is based on the detection of optical path-length delays in a stain-free manner, thereby providing a refractive index which directly correlates to tissue density. this study aims to evaluate the role of dhm for quantifying the degree of histological inflammation in endoscopically acquired biopsies of uc patients in a prospective clinical trial. from 28 uc patients, the investigators will obtain endoscopically acquired colonic biopsies. the investigators will assess the degree of inflammation in these biopsies using dhm and in addition to this an experienced histopathologist will determine the degree of inflammation in these biopsies using a histological scoring system (nancy-score = goldstandard). finally, the investigators will directly correlate the results from dhm analysis to the histological analysis using the nancy-score.


Eligibility criteria:
inclusion criteria: - patients with an indication for a colonoscopy exclusion criteria: * patients under 18 years, pregnancy * inability to have a patient education * bad conditions or other reasons prohibiting a colonoscopy